10X Capital Venture Acquisition III (10X Capital Venture Acquisition III) ROCE % : -26.80% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 10X Capital Venture Acquisition III ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 10X Capital Venture Acquisition III's annualized ROCE % for the quarter that ended in Sep. 2023 was -26.80%.

10X Capital Venture Acquisition III ROCE % Historical Data

The historical data trend for 10X Capital Venture Acquisition III's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10X Capital Venture Acquisition III ROCE % Chart

10X Capital Venture Acquisition III Annual Data

Trend

Dec21

Dec22

ROCE %

-17.52

10X Capital Venture Acquisition III Quarterly Data
	Feb21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial						-0.44	-5.23	-13.72	-21.58	-26.80

10X Capital Venture Acquisition III ROCE % Calculation

10X Capital Venture Acquisition III's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-3.463	/	( ( (0.567 - 0.587)	+	(308.855 - 269.308) )	/ 2 )
	=	-3.463	/	( (-0.02	+	39.547)	/ 2 )
	=	-3.463	/	19.7635
	=	-17.52 %

10X Capital Venture Acquisition III's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-10.588	/	( ( (44.692 - 4.153)	+	(43.995 - 5.524) )	/ 2 )
	=	-10.588	/	( ( 40.539	+	38.471 )	/ 2 )
	=	-10.588	/	39.505
	=	-26.80 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

10X Capital Venture Acquisition III (AMEX:VCXBU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

10X Capital Venture Acquisition III ROCE % Related Terms

Thank you for viewing the detailed overview of 10X Capital Venture Acquisition III's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

10X Capital Venture Acquisition III (10X Capital Venture Acquisition III) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » 10X Capital Venture Acquisition Corp III (AMEX:VCXBU) » Definitions » ROCE %

Comparable Companies

BCSA LCW GAQ FLME CHEA EVE HCMA SUAC ALCY HHLA PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA

Traded in Other Exchanges

VCXB:USA

Address

1 World Trade Center, 85th Floor, New York, NY, USA, 10007

Website

https://www.10xspac.com

10X Capital Venture Acquisition Corp III is a blank check company.

10X Capital Venture Acquisition III (10X Capital Venture Acquisition III) Headlines

From GuruFocus

Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III

By GlobeNewswire • 08-10-2023